Immunome Stock Investor Sentiment
| IMNM Stock | USD 13.47 1.94 16.83% |
About 56% of all Immunome's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Immunome suggests that some traders are interested. Immunome's investing sentiment overview a quick insight into current market opportunities from investing in Immunome. Many technical investors use Immunome stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Immunome |
Immunome Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Immunome can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Immunome that are available to investors today. That information is available publicly through Immunome media outlets and privately through word of mouth or via Immunome internal channels. However, regardless of the origin, that massive amount of Immunome data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunome news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunome relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunome's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunome alpha.
Immunome Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology Congres... | 09/13/2024 |
2 | Disposition of 14380 shares by Max Rosett of Immunome at 16.01 subject to Rule 16b-3 | 09/19/2024 |
3 | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 10/08/2024 |
4 | Immunome Acquires Zentalis Pharmaceuticals Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceutic... | 10/30/2024 |
5 | Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference | 11/05/2024 |
6 | FMR LLCs Strategic Acquisition of Immunome Inc Shares | 11/13/2024 |
7 | Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc | 11/15/2024 |
8 | Acquisition by Clay Siegall of 33943 shares of Immunome at 9.7787 subject to Rule 16b-3 | 11/22/2024 |
9 | Insider Buying Robert Lechleider Acquires Shares of Immunome Inc | 11/25/2024 |
Check out Immunome Hype Analysis, Immunome Correlation and Immunome Performance. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.